GlassScriptPhysician profile
Concetta M Poidomani
NPI 1689924482
$2,209.48
in general payments reported to CMS, 2019-2025
21 companies · $733 in 2025
The $733 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $241 · 2023: $519 · 2024: $481 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $267.67 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $264.72 | 2023-2024 | Eliquis, Camzyos |
| Exeltis, USA INC. | $216.87 | 2023-2025 | Slynd |
| Mayne Pharma Commercial LLC | $169.84 | 2023-2025 | |
| Mylan Specialty L.P. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Descovy |
| Abbvie INC. | $118.71 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.28 | 2025 | |
| Boston Scientific Corporation | $112.63 | 2025 | Advantage System |
| Dexcom, INC. | $106.64 | 2024 | Dexcom G6 Transmitter |
| Mallinckrodt Hospital Products INC. | $100.00 | 2025 | Acthar |
| Novo Nordisk INC | $100.00 | 2025 | |
| Lilly USA, LLC | $99.18 | 2025 | Zepbound |
| Glaxosmithkline, LLC. | $88.04 | 2023 | Bexsero |
| Biogen, INC. | $83.22 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $37.27 | 2023-2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Sage Therapeutics, LLC | $22.28 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $19.71 | 2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $15.61 | 2024 | Paragard T 380a |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Organon LLC | $8.81 | 2023 | Nuvaring, Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Concetta Poidomani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.